Telmisartan to prevent recurrent stroke and cardiovascular events. - Wikidata - wikimedia - TriplyDB

Telmisartan to prevent recurrent stroke and cardiovascular events.

Telmisartan to prevent recurrent stroke and cardiovascular events.

http://www.wikidata.org/entity/Q34596294

about

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?PPARs: Protectors or Opponents of Myocardial Function?Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring Understanding and treating hypertension in diabetic populations Renin-angiotensin system blockade: Its contribution and controversy Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Telmisartan and cardioprotection Pre-hypertension: how low to go and do drugs have a role?Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Therapeutic potential of the renin angiotensin system in ischaemic stroke Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events Renin-angiotensin system blockade for the risk of cancer and death.Comparing angiotensin II receptor blockers on benefits beyond blood pressure A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors Joint Commission primary stroke center certification does not affect proband enrollment: the siblings with ischemic stroke study Salt intake and cardiovascular disease: why are the data inconsistent?Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis.Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey.Blood pressure and diabetic nephropathy Management of Hypertension Using Olmesartan Alone or in Combination Blood Pressure Management for Stroke Prevention and in Acute Stroke Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788].2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations.The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR).Antihypertensive drugs and glucose metabolism Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease.

P2860

Q24288920-D25FB5A9-473B-407A-A66D-AEC230FB5E2B Q24645205-D89D5BD8-1E95-44D5-A6B8-D5DD518F8EC7 Q26747669-47C02C8E-D590-48CC-A225-453DE0C41FFF Q26764784-2E651F79-4350-4F55-8A23-86FAC3C7C4B8 Q26766025-6863F5FC-C201-4B14-99AE-6789A1C6FEAE Q26767278-5EC293B3-E5C8-49EC-A3CA-44DA5E43546E Q26768696-AA7B21D5-8D92-41AD-A9C8-02BD5B60692D Q26771753-3B2C2826-A958-4BCA-A965-869EEAE22244 Q26774683-F9D533C3-E65B-43B5-8E1B-3E7A3D89D924 Q26778662-C2F89613-E362-4179-B995-799A5F96DADF Q26827221-D56FD69C-7F9D-43FD-B4C9-D7D869E1AA37 Q26851803-55876713-0B73-4BF9-841A-AADA56419553 Q26861422-15A361E2-1930-440E-B7D9-32904451EF8A Q27007552-B7F827B5-0C48-48E1-B285-C64A89F66DCA Q27023161-EC542D02-5956-4AF3-8B0D-51296FD14DCA Q28077553-941453E7-8624-4DCC-AE65-AAF0AFDA28A9 Q28087109-E2FAFB36-DD47-46BC-BA63-BAC6A22CA9CF Q28476590-EA66D729-7819-43E7-9A40-B1155CB3D480 Q30249043-59038ED2-E11F-4ABC-A447-193AE94D13EA Q30360678-99502215-C15C-4798-8131-F8DC069EC169 Q30432209-727B8144-D197-4B42-9B4F-11A5AADD93E6 Q30438484-6CA0DA66-55A3-41B2-9A0C-88D5249A3BB2 Q30582625-624608FB-240C-4E90-B3AF-9FEE566DDF24 Q30619473-F1562C3B-A27E-42EA-9694-6991924793B1 Q30634009-E748273D-F263-4DC5-949F-5544DC9838DC Q33403831-B1392329-F734-4791-A064-E9DAF5AF23E4 Q33681738-6B65BC5C-966B-4D6C-A996-3A40A9C8ECF5 Q33683851-47306D20-411A-4817-89F1-FB7405684FE1 Q33734043-9A8BB68C-40E3-4734-BBF1-5FC77DBDD9AF Q33783596-289BFE72-6817-4FAD-9EF1-E49E151C9D53 Q33798432-AC59D12D-007B-4A6C-8671-CED3A55F220F Q33803829-9B6AFECA-49C4-437F-B49D-841186C52FCA Q33843433-544723DC-A0FD-4C5D-B94D-C3F047A3AC23 Q33916665-248FEEFF-2037-4DF9-95B2-827F97178BBE Q33916677-C4F79E52-BB71-41C0-9F2F-7E3EC9A65F2F Q33933485-38E0E119-30E3-4EA4-AA8C-50D22AE321CD Q33948469-6C89AE20-9E90-4A19-809E-BC838A5620E8 Q33967781-08D74CAE-E5CD-473D-9405-233B78CFCC22 Q33994970-E5420A89-981C-4B58-9C0C-02FBEA17A303 Q34010411-915B7AA0-C3F4-4382-B4FB-D893B4A9E443

P2860

Telmisartan to prevent recurrent stroke and cardiovascular events.

http://www.wikidata.org/entity/Q34596294

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Telmisartan to prevent recurrent stroke and cardiovascular events.

@ast

Telmisartan to prevent recurrent stroke and cardiovascular events.

@en

Telmisartan to prevent recurrent stroke and cardiovascular events.

@nl

type

label

Telmisartan to prevent recurrent stroke and cardiovascular events.

@ast

Telmisartan to prevent recurrent stroke and cardiovascular events.

@en

Telmisartan to prevent recurrent stroke and cardiovascular events.

@nl

prefLabel

Telmisartan to prevent recurrent stroke and cardiovascular events.

@ast

Telmisartan to prevent recurrent stroke and cardiovascular events.

@en

Telmisartan to prevent recurrent stroke and cardiovascular events.

@nl

P1433

Q34596294-E5F45410-3E41-4E20-A2EF-68889D4D617F

P1476

Q34596294-07134EA2-CC7E-48E9-9D1C-AC04C3F209C4

P2093

Q34596294-10088DBA-DCAD-4224-9B3C-63810CEFD6F7

Q34596294-13AC1B1B-0475-40E3-9E3F-BCC85362F1E0

Q34596294-2097FA6A-9BA0-41FC-8334-45C5EBD7E7F0

Q34596294-29D4C848-330F-43AE-87D1-D75D0CD0D753

Q34596294-30E5F30D-8CB5-4627-85E3-583FFC98F30A

Q34596294-3E290D9E-D973-4F47-867B-A45B16C15AD4

Q34596294-3F32FBE5-18CA-4D01-B4D2-F347DC90693B

Q34596294-4772AAC4-ADB7-4BBC-8896-633886E11DD5

Q34596294-5A8E4CA4-C805-48B4-A0F3-F9D647F07709

Q34596294-62ACD1BC-947C-4CEC-A008-8CD1706A61A6

P2860

Q34596294-0C47DDF3-EA1A-4168-B44A-2A601C9E3EF8

Q34596294-0D312C84-C745-4B7F-BE07-E8DDBAFAC8B4

Q34596294-1C595228-F3B3-4F00-88D8-E5CD7AB58F2C

Q34596294-27812D01-FB52-4CB2-8995-F2D60FD70376

Q34596294-37FBB1C7-8F0F-4961-95D4-E956B35ADC9E

Q34596294-4577D53E-4C7B-45BD-8FE4-F923D9AE6B7E

Q34596294-5214F7A9-3528-46DE-8AB6-E6AFF5AFC091

Q34596294-54CC8C79-E3C5-4A89-922A-FAE82F2E2351

Q34596294-66D3A1C1-64D7-437E-A181-5467853AD32B

Q34596294-6E75032B-CB42-43A8-8714-67CA5E5EC481

P304

Q34596294-1B5F9DFA-05ED-46ED-BE30-7144776E15E5

P31

Q34596294-0BCA195C-E6CA-477A-8BD9-5D4EF4F694B3

P356

Q34596294-CE725978-C071-4341-B7CB-EC02E7DC4192

P407

Q34596294-6CFA868C-86C8-46AB-83AF-6E2D9535ED9B

P433

Q34596294-6676E7C7-6B16-442B-8A98-05AC0C41150C

P478

Q34596294-44B0F91C-F8F4-482D-BF24-278B608517AD

P50

Q34596294-23BD1CDE-9D08-457F-A3DE-7ED602673F68

Q34596294-2AC28874-6FFF-46E5-8A1C-0BCF7D768DFD

Q34596294-5BF843AB-621B-4D4E-8DDD-B22375E0B0DE

Q34596294-665BA129-E2BD-4022-8B87-549F337BC3FB

Q34596294-6CB01AA3-1340-4556-9B73-D42EF3E6C535

Q34596294-94F021AD-292C-461B-BF7E-171E91899E3F

Q34596294-AAE4FF3C-32E8-4680-A529-1AB4CFD05B6F

Q34596294-C56B56D1-64E6-475B-8B30-8EAE4C0F35E7

Q34596294-D7A1E993-7840-4636-9AF5-634D56344E24

P577

Q34596294-858646B9-F16F-4794-9684-AA78EDCBA2D1

P698

Q34596294-94415D21-99FF-4211-B25B-9BB73D227FB8

P921

Q34596294-CCCC7FB3-7C0A-415A-82E9-B86753DB429B

P932

Q34596294-314D3DC8-4626-4B49-A91F-96E4A48D1DFD

P356

P1433

The New England Journal of Medicine

P1476

Telmisartan to prevent recurrent stroke and cardiovascular events.

@en

P2093

Bernard P L Chan

http://www.w3.org/2001/XMLSchema#string

Byung-Woo Yoon

http://www.w3.org/2001/XMLSchema#string

Cam VanderMaelen

http://www.w3.org/2001/XMLSchema#string

Chuanzhen Lu

http://www.w3.org/2001/XMLSchema#string

Conrado Estol

http://www.w3.org/2001/XMLSchema#string

Daniel Cotton

http://www.w3.org/2001/XMLSchema#string

Danilo Toni

http://www.w3.org/2001/XMLSchema#string

Gregory W Albers

http://www.w3.org/2001/XMLSchema#string

Karin Hermansson

http://www.w3.org/2001/XMLSchema#string

Lutz Hilbrich

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Blood pressure and clinical outcomes in the International Stroke Trial

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events

Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patient

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Effect of ramipril on the incidence of diabetes.

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

P304

1225-1237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0804593

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Christoph Diener

Jacques De Keyser

Geoffrey A. Donnan

Philip M W Bath

P577

2008-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18753639

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2714258

http://www.w3.org/2001/XMLSchema#string